Skip to main content
main-content

16.06.2017 | Review Article | Ausgabe 9/2017

Supportive Care in Cancer 9/2017

Biomarkers in the assessment of oral mucositis in head and neck cancer patients: a systematic review and meta-analysis

Zeitschrift:
Supportive Care in Cancer > Ausgabe 9/2017
Autoren:
Ana Gabriela Costa Normando, Camila Lopes Rocha, Isabela Porto de Toledo, Paulo Tadeu de Souza Figueiredo, Paula Elaine Diniz dos Reis, Graziela De Luca Canto, Eliete Neves Silva Guerra
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s00520-017-3783-8) contains supplementary material, which is available to authorized users.

Abstract

Purpose

The aim of this study was to evaluate the capability of biomarkers to predict the risk of oral mucositis in head and neck cancer patients, as well as to assess the correlation between these biomarkers and the severity of mucositis.

Methods

The search was performed at LILACS, PubMed, Science Direct, Scopus, and Web of Science. A search of the gray literature was performed on Google Scholar, OpenGrey, and ProQuest. The methodological quality of the included studies was assessed using the Meta-Analysis of Statistics Assessment and Review Instrument (MAStARI) tool, and the evidence quality was assessed by the Grading of Recommendation, Assessment, Development, and Evaluation (GRADE) system.

Results

After a two-step selection process, 26 studies met the eligibility criteria. In total, 27 biomarkers were evaluated, and the most frequent were the epidermal growth factor (EGF), C-reactive protein (CRP), genetic polymorphisms, tumor necrosis factor alpha (TNF-α), and erythrocyte sedimentation rate (ESR). The meta-analysis showed an expression of polymorphisms in XRCC1 (32.66%), XRCC3 (31.00%), and RAD51 (39.16%) genes, as well as an expression of protein biomarkers (39.57%), in patients with an increased risk of developing oral mucositis.

Conclusions

Dosing biomarkers before starting radiation therapy may be a promising method to predict the risk of developing mucositis and allow radiosensitive patients to have a customized treatment. Although there is currently limited evidence to confirm the putative implementation of serum and salivary biomarkers to assess the correlation between them and the severity of mucositis, this current review provides new research directions.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

★ PREMIUM-INHALT
e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Weitere Produktempfehlungen anzeigen
Zusatzmaterial
ESM 1 (DOCX 500 kb).
520_2017_3783_MOESM1_ESM.docx
ESM 2 (DOCX 511 kb).
520_2017_3783_MOESM2_ESM.docx
ESM 3 (DOC 67 kb).
520_2017_3783_MOESM3_ESM.doc
ESM 4 (DOCX 36 kb).
520_2017_3783_MOESM4_ESM.docx
ESM 5 (DOCX 24 kb).
520_2017_3783_MOESM5_ESM.docx
ESM 6 (DOCX 19 kb).
520_2017_3783_MOESM6_ESM.docx
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 9/2017

Supportive Care in Cancer 9/2017Zur Ausgabe
  1. Das kostenlose Testabonnement läuft nach 14 Tagen automatisch und formlos aus. Dieses Abonnement kann nur einmal getestet werden.

Neu im Fachgebiet Onkologie

Mail Icon II Newsletter

Bestellen Sie unseren kostenlosen Newsletter Update Onkologie und bleiben Sie gut informiert – ganz bequem per eMail.

Bildnachweise